Agents in Development for Anxiety DisordersCurrent Status and Future Potential
作者:
Sean D. Hood,
Spilios V. Argyropoulos,
David J. Nutt,
期刊:
CNS Drugs
(ADIS Available online 2000)
卷期:
Volume 13,
issue 6
页码: 421-431
ISSN:1172-7047
年代: 2000
出版商: ADIS
关键词: Abecarnil, therapeutic use;Anxiety disorders, treatment;Anxiolytics, therapeutic use;CI 988, therapeutic use;Deramciclane, therapeutic use;Dopamine antagonists, therapeutic use;Gabapentin, therapeutic use;Gepirone, therapeutic use;Girisopram, therapeutic
数据来源: ADIS
摘要:
Benzodiazepines have been used as anxiolytics for many years, despite well described withdrawal effects and drug interactions. Serotonergic antidepressants, which benefit from a favourable adverse effect profile and do not cause dependence, are now established first-line treatments for anxiety disorders. It is apparent, however, that current treatments are not ideal, particularly as they do not always produce a complete recovery. Our growing knowledge of the neurobiology of anxiety disorders, aided by advances in neuroimaging and pharmacological challenges, has led to the development of other potential anxiolytics.Agents with increased specificity for serotonin receptor subtypes have been developed, with the aim of maximising therapeutic efficacy while minimising adverse effects. Novel anxiolytics, such as neuropeptide agonists and antagonists, γ-aminobutyric acid (GABA)Areceptor partial agonists, N-methyl-D-aspartate (NMDA) receptor antagonists, neurosteroids and others, are currently in development and may eventually offer alternatives to currently available agents.
点击下载:
PDF
(146KB)
返 回